摘要
目的评价应用注射用A群链球菌在乳腺癌治疗中的价值。方法2011年1～12月上海交通大学医学院附属新华医院普外科建立乳腺癌的动物模型，局部应用注射用A群链球菌后观察瘤重和肿瘤直径以及相关免疫指标的变化；30例乳腺癌病人术中应用注射用A群链球菌，观察病人术后引流量、创口及血液中免疫指标的变化。结果在乳腺癌模型中，注射用A群链球菌对乳腺癌瘤体的肿瘤抑制率为32．48％，白介素-6（IL-6）、白介素-12（IL-12）和转化生长因子-β（TGF—β）的表达量较未应用者明显升高。临床病人应用注射用A群链球菌后，术后5d引流量降低20％～30％，创口恢复良好，免疫相关指标CD4／CD8比值由2．23变为1．74，免疫系统恢复正常，自然杀伤细胞（NK）的数量较未使用注射用A群链球菌的病人无明显变化，所有病人均未出现明显的不良反应。结论注射用A群链球茵在乳腺癌治疗中有较好疗效，可以增强宿主的抗肿瘤免疫功能。
Objective To evaluate the value of Sapylin in the treatment of breast cancer. Methods On the basis of establishing an animal model of breast cancer, local injection of Sapylin was used to observe changes in tumor weight, tumor diameter and immune parameters. Thirty cases of breast cancer patients were performed treatment of Sapylin. The postoperative drainage, wound and blood changes in immune parameters were observed. Results In the breast cancer model, the tumor inhibition rate of Sapylin is 32.48%, and the expressions of IL-6, IL-12 and TGF-13were significantly improved compared with the control group. The drainage was reduced 20%-30% in the 5th day after operation, and wound recovery of clinical patients with treatment of Sapylin was in good condition. The CD4/CD8 turned from 2.23 to 1.74, which was to say that the immune system got fight, and there was no improvement in the number of NK cell than patients without Sapylin. There was no apparent adverse reaction. Conclusion Sapylin has nice efficacy in the treatment of breast cancer, and could enhance the anti-tumor immunity of the host.
出处
《中国实用外科杂志》
CSCD
北大核心
2013年第3期201-204,共4页
Chinese Journal of Practical Surgery
